PartnershipJul 7, 2026, 05:11 PM
Praxis Partners with Remagine Labs for Ulixacaltamide Transdermal Patch
AI Summary
Praxis Precision Medicines, Inc. announced a research collaboration and license agreement with Remagine Labs, Inc. to develop an iontophoretic transdermal patch for the delivery of ulixacaltamide, targeting essential tremor. This partnership aims to leverage Remagine's proprietary platform for precise, multi-day active transdermal dosing, thereby broadening the potential patient population and enhancing ulixacaltamide's market position. Praxis also made an equity investment in Remagine to support the program's advancement.
Key Highlights
- Praxis Precision Medicines entered a research collaboration and license agreement with Remagine Labs.
- The partnership aims to develop an iontophoretic transdermal patch for ulixacaltamide.
- The transdermal patch is intended for the delivery of ulixacaltamide for essential tremor.
- Remagine's proprietary platform for precise, multi-day active transdermal dosing will be utilized.
- The transdermal option seeks to broaden ulixacaltamide's reach and strengthen its competitive position.
- Praxis Precision Medicines made an equity investment in Remagine Labs.
Price Impact
More from PRAX